Patent · US Active

Genetically modified mesenchymal stem cell that express an exogenous cytotoxic protein

US9434925B2 · kind B2 · utility

3Cited by

0References

30Claims

0Family size

Assignee

APCETH GMBH & CO. KG · DE

Inventor

Peter J. Nelson · Sydney, AU

Key dates

Filing date	Apr 13, 2010
Grant date	Sep 6, 2016
Priority date	—
Expiry date	Aug 29, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/002
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified mesenchymal stem cells come into proximity with the tumor's stromal tissue. This invention further provides genetically modified mesenchymal stem cells for use in this method.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.